ReviewCritical care (London, England)2011
New treatment options against gram-negative organisms.
Review in Critical care (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extended spectrum beta-lactamase and carbapenemase-producing Acinetobacter species and Pseudomonas aeruginosa in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Hybrid Genome and Clinical Impact of Emerging Extensively Drug-Resistant Priority Bacterial PathogenLife (Basel, Switzerland) · 2025Article
- In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form-alone and in combination with bacteriophages.Scientific reports · 2025Article
- Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.npj antimicrobials and resistance · 2023Review
- Antimicrobial Resistance and Extended-Spectrum Beta-Lactamase Genes inPathogens (Basel, Switzerland) · 2023Article
- The Major Facilitator Superfamily and Antimicrobial Resistance Efflux Pumps of the ESKAPEE PathogenAntibiotics (Basel, Switzerland) · 2023Review
- The Potential of Antibiotics and Nanomaterial Combinations as Therapeutic Strategies in the Management of Multidrug-Resistant Infections: A Review.International journal of molecular sciences · 2022Review
- Late-Stage Modification of Aminoglycoside Antibiotics Overcomes Bacterial Resistance Mediated by APH(3') Kinases.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Gold nanoparticle-DNA aptamer-assisted delivery of antimicrobial peptide effectively inhibits Acinetobacter baumannii infection in mice.Journal of microbiology (Seoul, Korea) · 2022Article
- Detrimental Effect of Ozone on Pathogenic Bacteria.Microorganisms · 2021Article
- Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (Journal of clinical medicine · 2021Review
- Screening of compound library identifies novel inhibitors against the MurA enzyme of Escherichia coli.Applied microbiology and biotechnology · 2021Article
- The magnitude of extended-spectrum beta-lactamase- producingAccess microbiology · 2021Review
- Article
- Overcoming Multidrug-Resistant MRSA Using Conventional Aminoglycoside Antibiotics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Fecal Carriage Rate of Extended-Spectrum Beta-Lactamase-ProducingInfection and drug resistance · 2020Article
- DNA double-strand break formation and repair as targets for novel antibiotic combination chemotherapy.Future science OA · 2019Review
- Chemical synthesis of tripeptide thioesters for the biotechnological incorporation into the myxobacterial secondary metabolite argyrin via mutasynthesis.Beilstein journal of organic chemistry · 2019Article
- High Prevalence of Multi-Drug Resistance and Extended Spectrum Beta Lactamase Production in Non-Fermenting Gram-Negative Bacilli in Ethiopia.Infectious diseases · 2019Article
- A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.